Clinical Trials

Aduro’s current clinical development programs are focused on potential treatments for a variety of cancers, including mesothelioma, lung and ovarian cancers, as well as a variety of other solid tumors and lymphomas.

Concurrently, Aduro works with investigators at leading medical institutions to extend our development efforts through investigator-sponsored trials (ISTs).

Program

Indication

Trial Number

Trial Name

 LADD® Programs

CRS-207 Mesothelioma NCT01675765 A Phase 1b Study to Evaluate the Safety and Induction of Immune Response of CRS-207 in Combination with Pemetrexed and Cisplatin as Front-line Therapy in Adults with Malignant Pleural Mesothelioma
CRS-207 Ovarian Cancer NCT02575807

A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination with Epacadostat in Adults with Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer (SEASCAPE)

ADU-741/JNJ-64041809 Prostate Cancer NCT02625857 An Open-Label, Phase 1 Study of the Safety and Immunogenicity of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Subjects with Metastatic Castration-resistant Prostate Cancer
ADU-214/JNJ-64041757 Lung Cancer NCT02592967 An Open Label Phase 1 Study of Safety and Immunogenicity of JNJ-64041757, A Live Attenuated Listeria Monocytogenes Immunotherapy, in Subjects with Non-Small Cell Lung Cancer

 STING Pathway Activator Programs

ADU-S100/MIW815 Multiple tumors NCT02675439 A Phase I, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients with Advanced/Metastatic Solid Tumors or Lymphomas

CRS-207

Lead Candidate from the LADD Platform

Aduro’s lead LADD therapeutic, CRS-207, has been engineered to stimulate an immune response to mesothelin, a tumor-associated antigen expressed by multiple tumor types that contributes to the malignant phenotype and has limited expression in normal tissue. CRS-207 is currently being studied in clinical trials in patients with mesothelioma and ovarian cancers.

ADU-S100

Lead Candidate from the STING Pathway Activators Platform

Aduro is developing ADU-S100, a novel synthetic molecule that activates human STING (Stimulator of INterferon Genes), in collaboration with Novartis. ADU-S100 is being evaluated in a Phase 1 clinical trial in cutaneously-accessible tumors, including breast, head-and-neck, and renal cell cancers as well as lymphoma and melanoma. The trial is evaluating the ability of ADU-S100 to activate the immune system and recruit specialized immune cells to attack the injected tumor as well as distant metastases.

BION-1301

Lead Candidate from the B-select Platform

BION-1301 is Aduro’s proprietary monoclonal antibody targeting APRIL, which the company intends to evaluate in patients with multiple myeloma. Preclinical studies demonstrated that BION-1301 halts tumor growth, overcomes drug resistance to  standard-of-care agents such as lenalidomide and bortezomib, and relieves immunosuppression. A phase 1 clinical trial is planned for 2017.